Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2008-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine how many patients with Parkinson's disease have compulsive behaviors, and what types of behaviors they have. This study will also determine if acamprosate can be used to treat compulsive behaviors in Parkinson's disease patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off

NCT00642356

Parkinson's Disease

TERMINATED PHASE4

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

NCT00099268

Parkinson's Disease

COMPLETED PHASE3

Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease

NCT00240409

Parkinson Disease

COMPLETED PHASE3

Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug

NCT04810104

Parkinson Disease Mild Cognitive Impairment

WITHDRAWN PHASE2

ACP-103 to Treat Parkinson's Disease

NCT00086294

Parkinson's Disease Dyskinesias

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acamprosate

333 mg 2 tabs tid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Idiopathic Parkinson's disease
2. Active dopaminergic therapy at stable dose for one month (levodopa or dopamine agonist)
3. Able and willing to complete Rating Scales
4. Presence of one or more compulsive behavior based on responses to Rating Scales (defined as \>5 on the SOGS; \>17 on the YBOCS-SV and YBOCS-CUV; \>1.7 on the SCS for women and \>2.1 on the SCS for men; \>15 on the YBOCS-BE, \>5.5 on the CQ).
5. Written informed consent

1. No significant psychiatric disease
2. Able and willing to complete Rating Scales
3. Written informed consent

Exclusion Criteria

1. No anticipated need for adjustment of medications for Parkinson's disease
2. Current participation in another clinical study
3. History of unstable psychiatric disease (as determined by the Principal Investigator)
4. Women of childbearing age not using appropriate contraceptive methods (oral contraceptives, condoms, surgery)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes